IntroductionNevadensin has a variety of pharmacological effects, including effects of anti-mycobacterium tuberculosis, antitussive, anti-hypertensive, anti-inflammatory, and free radical-scavenging activities. In this study, we investigated for their anticholinergics, antidiabetic, and anti-human oral squamous cell carcinoma potentials for nevadensin. Material and methodsThe antioxidant activities of nevadensin were elucidated by using various bioanalytical assays. On the other hand, IC50 values were calculated for acetylcholine esterase, α-glucosidase inhibition effects of nevadensin. For determining of anti-human oral squamous cell carcinoma properties of nevadensin, MTT assay was used on HUVEC, HSC-3, HSC-4, and Ca9-22 cell lines. The molecular docking method used to compare the biological activities of the nevadensin molecule against enzymes was used. Afterwards, the ADME/T analysis was performed to investigate the drug availability of the nevadensin molecule and the obtained parameters from ADME/T analysis were examined.ResultsThe cell viability of nevadensin was very low against human oral squamous cell carcinoma cell lines without any cytotoxicity on the human normal (HUVEC) cell line. The IC50 of the nevadensin against HSC-3, HSC-4, and Ca9-22 were 316, 273, and 399 µg/mL, respectively. Thereby, the best cytotoxicity results and anti-human oral squamous cell carcinoma potentials of our nevadensin was observed in the case of the HSC-4 cell line. ConclusionsMaybe the anti-human lung carcinoma properties of nevadensin are related to their antioxidant effects.